Redeye comments on Scandion Oncology’s Q3 2022 report, some one month after the company has recruited the first of up to 36 patients to its phase II CORIST part 3 dose-finding arm. We adjust our estimates and fair value range to reflect current capital market conditions.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.